华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 部分募投项目终止及部分募投项目延期的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐人"）作为 江苏东星智慧医疗科技股份有限公司（以下简称"东星医疗"或"公司"）首 次公开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市 保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求》《深圳证券交易所创业板股票上市规则》及《深圳证券交易 所上市公司自律监管指第 2 号——创业板上市公司规范运作》等相关法律法规、 规范性文件的要求，对东星医疗本次部分募投项目终止及部分募投项目延期的 事项进行了审慎核查，并发表本核查意见，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意江苏东星智慧医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1922 号）同意注册，并经 深圳证券交易所同意，公司首次向社会公众公开发行人民币普通股（A 股） 2,504.3334 万股，每股发行价为人民币 44.09 元，募集资金总额为人民币 1,104,160,596.06 元 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-027 江苏东星智慧医疗科技股份有限公司 关于部分募投项目终止及部分募投项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开第四届董事会第十一次会议以及第四届监事会第十次会议，审议通过 了《关于部分募投项目终止的议案》《关于部分募投项目延期的议案》，公司拟 对首次公开发行股票募投项目"孜航医疗器械零部件智能制造及扩产项目"予以 终止。同时，公司根据当前募投项目的实际建设情况、投资进度以及结合吻合器 行业和市场需求发展情况，在保证募集资金投资项目实施主体、实施方式和投资 总额不变的情况下，将募投项目"威克医疗微创外科新产品项目"达到预定可使 用状态日期延期至 2027 年 12 月 31 日。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-028 江苏东星智慧医疗科技股份有限公司 关于召开公司2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于2025年6月23日召 开了第四届董事会第十一次会议，审议通过了《关于提请召开2025年第一次临 时股东大会的议案》，董事会决定于2025年7月10日（星期四）下午2:30在公司 会议室召开2025年第一次临时股东大会。为了进一步保护投资者的合法权益， 方便公司股东行使表决权，本次股东大会将采用现场投票与网络投票相结合的 方式，根据有关规定，现将股东大会的相关事项通知如下： 一、会议召开基本情况 1、股东大会届次：2025年第一次临时股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第十一次会议审议通过了 《关于提请召开2025年第一次临时股东大会的议案》，本次股东大会的召开符 合有关法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和 《公司章程》的规定。 4、 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-026 一、监事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 6 月 23 日 14:00 在公司会议室以现场方式召开。本次会议通 知已于 2025 年 6 月 19 日通过邮件的方式送达全体监事。本次会议由监事会主席 朱慧玲主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席会 议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。 江苏东星智慧医疗科技股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： （一）审议通过《关于部分募投项目终止的议案》 经审议，监事会认为：公司本次终止部分募投项目的事项，是结合募投项目 的投资进度和实际建设情况，经审慎评估后作出的决定，不存在损害公司及股东 利益的情形，不会对公司的正常生产经营产生不利影响，符合公司长期发展规划 和全体股东的利益。本次 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-025 江苏东星智慧医疗科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第十 一次会议于 2025 年 6 月 23 日 8:45 在公司会议室以现场结合通讯的方式召开。 本次会议通知已于 2025 年 6 月 19 日通过邮件的方式送达全体董事。本次会议应 出席董事 7 人，实际出席董事 7 人，其中独立董事沈世娟女士、朱旗先生、上官 俊杰先生以通讯方式出席会议。会议由董事长万世平先生召集并主持，公司监事、 高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合《公司 法》等有关法律法规及《公司章程》的相关规定。 二、董事会会议审议情况 （一）审议通过《关于部分募投项目终止的议案》 公司对首次公开发行股票募投项目"孜航医疗器械零部件智能制造及扩产项 目"予以终止，上述募投项目终止后，公司将该项目节余募集资金继续留存于其 专户进行管理。 公司保荐人出 ...

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

东星医疗（301290）公告，控股子公司常州东星生物医药有限公司与上海交通大学签订了《技术开发 (委托)合同》，合同总金额共计600万元。合同包括截断(短链)重组Ⅲ型人源化胶原蛋白和全长(长链)重 组Ⅲ型人源化胶原蛋白两个项目，每个项目合同约定的技术开发(委托)总额为300万元。 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-024 江苏东星智慧医疗科技股份有限公司 关于控股子公司与上海交通大学 签订技术开发（委托）合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，江苏东星智慧医疗科技股份有限公司（以下简称"公司"）控股子公 司常州东星生物医药有限公司（以下简称"东星生物"）与上海交通大学签订了 《技术开发（委托）合同》，现将相关情况公告如下： 为进一步深化公司产业布局，东星生物与上海交通大学签订了《技术开发（委 托）合同》，合同总金额共计 600 万元。通过本次校企联合，充分利用企业和高 等院校的互补资源，推动科研成果产业化，丰富公司产品模块，提升公司核心竞 争力。 6、上海交通大学简介：上海交通大学是教育部直属并与上海市共建的全国 重点大学，位列国家"双一流"、"985 工程"、"211 工程"重点建设高校， 是中国顶尖、享誉国际的研究型大学，拥有微生物代谢国家重点实验室等多个国 家级重点实验室及前沿交叉平台。 7、实施团队简介：本次项目将由中国科学院院士、上海交通大学生命科学 技术学院名誉院长和微 ...

Company Overview - Dongxing Medical closed at 24.09 yuan on May 20, with an increase of 1.52%, resulting in a rolling PE ratio of 26.93 times and a total market value of 2.413 billion yuan [1] - The company ranks 58th in the medical device industry, which has an average PE ratio of 49.51 times and a median of 36.17 times [1] Financial Performance - For Q1 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross profit margin of 44.40% [1] Capital Flow - On May 20, the net inflow of main funds into Dongxing Medical was 1.2033 million yuan, with a total inflow of 11.8631 million yuan over the past five days [1]